Loading stock data…
$2.57-0.18 (-6.55%)
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
Silexion Therapeutics Corp in the Healthcare sector is trading at $2.57 with a market capitalization of $3M. Wall Street consensus targets $60.00 (2 analysts), implying a +2234.6% move over the next 12 months. The stock is currently near its 52-week low of $2.31, remaining 86.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 10 is oversold, raising the odds of a near-term bounce. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.75M↑ | -$4.41M↓ | -$3.29M↓ | -$2.28M↓ | -$1.65M |
| Net Income | -$2.73M↑ | -$4.41M↓ | -$3.26M↓ | -$2.50M↓ | -$1.74M |
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its propriet...